

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**POST-EFFECTIVE AMENDMENT  
TO  
FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**HALOZYME THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

Delaware

88-0488686

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

11388 Sorrento Valley Road  
San Diego, CA

92121

(Address of principal executive offices)

(Zip Code)

**HALOZYME THERAPEUTICS, INC. 2004 STOCK PLAN  
NONSTATUTORY STOCK OPTION AGREEMENT WITH ANDREW KIM  
ASSUMED OPTIONS UNDER THE DELIATROPH PHARMACEUTICALS, INC. AMENDED AND RESTATED 2001 STOCK PLAN  
(Full title of the plan)**

**Harry J. Leonhardt**

**Senior Vice President, General Counsel**

**11388 Sorrento Valley Road**

**San Diego, CA 92121**

(Name and address of agent for service)

**(858) 794-8889**

(Telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

## DEREGISTRATION OF SECURITIES

This Post-Effective Amendment (the “**Post-Effective Amendment**”) relates to the Registration Statement on Form S-8 (Registration No. 333-119969) initially filed by Halozyme Therapeutics, Inc., a Delaware corporation (the “**Company**”) with the U.S. Securities and Exchange Commission on October 26, 2004 (as amended on September 19, 2008, the “**Registration Statement**”) to register a total of 10,125,000 shares of the Company’s common stock, par value \$0.001 per share (“**Common Stock**”), for issuance and sale of (i) up to 3,113,193 shares of Common Stock granted under the Halozyme Therapeutics, Inc. 2004 Stock Plan (the “**2004 Plan**”), (ii) up to 6,886,807 shares under the options to purchase Common Stock granted under the Deliatroph Pharmaceuticals, Inc. Amended And Restated 2001 Stock Plan (the “**Deliatroph Plan**”) that were assumed by the Company, and (iii) up to 125,000 shares under a non-statutory stock option agreement issued outside of the 2004 Plan and the Deliatroph Plan that was also assumed by the Company. As of the date of this Post-Effective Amendment, each of the 2004 Plan and the Deliatroph Plan has terminated, no awards remain outstanding under either of the 2004 Plan or the Deliatroph Plan, no additional shares of Common Stock will be issued under either of the 2004 Plan or the Deliatroph Plan and the options issued outside of the 2004 Plan and the Deliatroph Plan have terminated, are no longer outstanding and will not result in the issuance of any additional shares of Common Stock.

In accordance with the Company’s undertaking in Part II, Item 9 of the Registration Statement, the Registrant hereby amends the Registration Statement to remove from registration all securities registered but remaining unsold, if any, under the Registration Statement and to terminate the effectiveness of the Registration Statement.

### PART II

#### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits

24 Power of Attorney (included in signature pages to this Registration Statement)

---

**SIGNATURE**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California, on this 14<sup>th</sup> day of May, 2019.

Halozyme Therapeutics, Inc.

By: /s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.

Helen I. Torley, M.B. Ch.B., M.R.C.P.

President and Chief Executive Officer

---

## SIGNATURES AND POWER OF ATTORNEY

Know all persons by these presents, that each person whose signature appears below constitutes and appoints Helen I. Torley, Laurie D. Stelzer, and Harry J. Leonhardt and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his substitute or substituted, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Act of 1933 this registration statement has been signed by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title(s)</u>	<u>Date</u>
<u>/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.</u> Helen I. Torley, M.B. Ch.B., M.R.C.P.	President, Chief Executive Officer, and Director (Principal Executive Officer)	May 14, 2019
<u>/s/ Laurie Stelzer</u> Laurie Stelzer	Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)	May 14, 2019
<u>/s/ Connie L. Matsui</u> Connie L. Matsui	Chairman of the Board of Directors	May 14, 2019
<u>/s/ Jean-Pierre Bizzari, M.D.</u> Jean-Pierre Bizzari, M.D.	Director	May 14, 2019
<u>/s/ Bernadette Connaughton</u> Bernadette Connaughton	Director	May 14, 2019
<u>/s/ James M. Daly</u> James M. Daly	Director	May 14, 2019
_____ Jeffrey W. Henderson	Director	
_____ Kenneth J. Kelley	Director	
<u>/s/ Mathew L. Posard</u> Mathew L. Posard	Director	May 14, 2019